Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CC-99282 + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CC-99282||CC99282|CC 99282|BMS-986369|BMS986369|BMS 986369||CC-99282 modulates cereblon E3 ubiquitin ligase, leading to degradation of the transcription factors Ikaros and Aiolos, potentially resulting in decreased tumor cell proliferation, enhanced apoptosis, and antitumor activity (Blood (2021) 138 (Supplement 1).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 18||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05788081||Phase II||CC-99282 + Nivolumab + Rituximab CC-99282 + Rituximab||Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab. (TOP-FLOR)||Not yet recruiting||1|
|NCT03930953||Phase I||CC-99282 CC-99282 + Rituximab||A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)||Recruiting||USA | ITA | FRA | ESP | CAN | BEL | AUT||7|